
    
      Eligible subjects will be randomized to LME636 or Dexamethasone in a 3:1 ratio at the time
      they present to the trial site with the AAU flare and will enter treatment for 28 full days.
      Subjects with worsening disease from Visit 2/Day 4 onward or subjects without improvement
      after 14 days of treatment will be discontinued from treatment, unmasked and treated with a
      rescue regimen at the discretion of the investigator.
    
  